CE2 (4) 60.9 ± 16.4% 56.8 ± 23.2% 4 0.05
Apheresis is an essential tool in the field of hematopoietic cell transplantation (HCT). Nowadays, PBSCs are almost exclusively used in adult and pediatric patients receiving autologous HCT to support the administration of high-dose chemotherapy. In the allogeneic setting, PBSC represents the most widely used hematopoietic progenitor cell source in adult patients, and has largely supplanted the use of bone marrow collections or cord blood units in adult recipients. 1 PBSCs are collected from individuals who received a mobilization treatment before apheresis sessions, in order to increase the number of circulating progenitor cells that egress from the bone marrow niches; acutely myelo-suppressive cytotoxic agents, hematopoietic growth factors -mainly rhG-CSF-and CXCR4 antagonists such as plerixafor all mobilize progenitor cells. Patients and donors starting treatment with G-CSF while having normal or near-normal blood counts quickly develop hyper-leukocytosis simultaneously with elevated circulating CD34+ cells; patients receiving rhG-CSF after acutely myelosuppressive chemotherapy are collected during the recovery phase of neutropenia, and therefore have on average lower numbers of WBCs at the time of collection. Additional applications are expected for apheresis and collection of blood mononuclear cells, driven in part by the development of innovative immune cell based therapies such as chimeric antigen receptor T cells. 2, 3 For years, PBSC collections have been performed with the same cell separators, one of them, Spectra (Terumo BCT, Lakewood, CO, USA), being used by a large majority of apheresis facilities. The field recently witnessed the commercialization of new generations of cell separators by several manufacturers. Whether these devices provide superior performances for blood mononuclear and hematopoietic progenitor cell collection when compared with historical equipment warrants evaluation. In response to national and international regulations and FACT-JACIE requirements, apheresis facilities need to validate these new devices before substitution of currently used machines. Performing 'mock aphereses' obviously raises ethical questions. Although easier to conduct, validation of a new cell separator through benchmarking with historical or contemporary patient populations is not an entirely satisfactory approach, as there is a large interindividual variability in persons who are candidates for apheresis; this was however used to generate data and evaluate the performances of the recently released Optia cell separator (Terumo BCT) in large groups of individuals, as reported in a limited number of publications.
To address these limitations, we designed a validation plan that relies on a comparative evaluation of the performances of the old (Spectra, historical 'gold standard', equipment that was first introduced in 1987, 28 years ago) and new (Optia, comparator, equipment that was first launched in 2007) generations of cell separators marketed by the same manufacturer (Terumo BCT). We collected data on circulating and collected CD34+ cells in individuals who underwent two consecutive mononuclear blood cell collections, either autologous or allogeneic, alternating the use of the two devices.
On the basis of our institutional algorithm for CD34+ cell collection, patients and donors who participated in this study were included when their peripheral blood (PB) CD34+ cell numbers on their first admission was between 20 and 40/μL, thus allowing to reasonably predict that two consecutive aphereses would be necessary to achieve the collection of the target number of CD34+ cells/kg. Poor mobilizers defined by CD34+ cell counts below 20/μL were excluded, as well as patients or donors with CD34+ cell numbers above 40/μL who are likely to be collected with only one apheresis.
Twenty-five individuals were collected twice consecutively, alternating Optia and Spectra; this included seven healthy donors, eight multiple myeloma patients, five lymphoma patients, three patients with acute leukemia and two patients with solid tumors. Our program still performs autologous transplant in a small subset of women with breast cancer; the presence of three patients with acute leukemia in this small series is more unusual as indications for high-dose chemotherapy supported with autologous transplantation have become exceptional in this setting; however, when needed, it is our experience that these patients usually modestly mobilize their CD34+ progenitors in response to rhG-CSF administered after consolidation therapy. Descriptive statistics were used to compute mobilization-and collection-related parameters. Comparisons were performed using the non-parametric Wilcoxon test for paired values. Computations were performed using Social Sciences Statistics at http://www. socscistatistics.com/.
Spectra was used first in 9 cases and Optia was used first in 16 cases. The total blood volume processed was comparable at session 1 (11 297 mL) and at session 2 (11 207 mL), which reflects our institutional procedure that aims at processing three blood volumes whenever clinically tolerated and technically possible. The percentage and absolute number of circulating PB CD34+ cells were measured on the second day of collection for 18 individuals. This allowed to evaluate the performances of the two cell separators, using both CD34+ cell enrichment (the ratio of CD34+ cells percentage in the collected cell product to the percentage of circulating PB CD34+ cells measured on the blood sample drawn immediately before cell collection), as well as by calculating CE2 as previously reported:
4 CE2 is an index of collection efficiency that can be calculated for each individual session, taking into account the pool of circulating CD34+ cells as evaluated from the measurement of circulating CD34+ cells and the total blood volume, as well as the number of collected CD34+ cells. Results are reported in Table 1 : there was no significant difference when comparing the two cell separators using a Wilcoxon test for paired samples, and our results with Optia were comparable to previously published data. 4 There was also no difference when comparing CD34+ cell enrichment or CE2 on day 1 vs day 2 (6.03 ± 3.81 vs 5.92 ± 4.25 and 49.8 ± 18.8% vs 58.1 ± 15.1%, respectively). There was no statistically significant correlation between the absolute number of PB circulating CD34+ cells, WBC or ANC and the performance of the cell processor measured by CD34+ cell enrichment or CE2 as described above; the calculated correlation coefficients r 2 are much different of 1 both for Optia and Spectra (Figures 1a and b) . Although there was no difference in collection efficiency or the volume of processed blood, there was a slight difference in collected CD34+ cell numbers, with borderline statistical significance that favored the use of Spectra; this may be related to the slightly higher number of circulating CD34+ cells before collection with Spectra; the difference was no longer significant when reintegrating the seven patients and pairs of aphereses for which peripheral blood CD34+ cell counts on day 2 were not available. Successive versions of the Optia device have been validated through benchmarking with the previous generation of cell separators, both for adult 5 and pediatric 6 patients, and for donors, 7 including the collection of allogeneic blood mononuclear cells (donor lymphocyte infusions) for the latter. 8 Most recently, the possibility of predicting the collected cell dose from the circulating CD34+ cell count was demonstrated for the Optia platform, 4 like that which had previously been done for the Spectra or COM.TEC platforms. [9] [10] [11] To our knowledge, and with one exception in the peculiar context of extracorporeal photochemotherapy, 12 our report is the first one that compares the Spectra and Optia cell separators in the same individuals, thus limiting the consequences of interindividual variability related to personal and medical history on the evaluation of the performance of the two devices. Our data suggest similar performances for the old and new cell processors in terms of the ability to collect CD34+ progenitors for further autologous or allogeneic transplantation.
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